Page last updated: 2024-12-11

cefmatilen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cefmatilen: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	6400678
CHEMBL ID	2104438
SCHEMBL ID	8445744
MeSH ID	M0378614

Synonyms (14)

Synonym
s-1090 ,
(6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-8-oxo-3-(2h-triazol-4-ylsulfanylmethylsulfanyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
unii-t750um24h8
t750um24h8 ,
(-)-(6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-8-oxo-3-(((v-trizol-4-ylthio)methyl)thio)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(z)-oxime
cefmatilen
s 1090
140128-74-1
(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-8-oxo-3-(2h-triazol-4-ylsulfanylmethylsulfanyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CHEMBL2104438
cefmatilen [inn]
S1090 ,
SCHEMBL8445744
gtpl10778

Research Excerpts

Toxicity

Excerpt	Reference	Relevance
" The lesions of urinary bladder were judged as S-1090-induced toxic changes and the NOAEL of S-1090 in this study was assessed to be 100 mg potency/kg/day."	( [Toxicity study of cefmatilen hydrochloride hydrate (S-1090) (7)--Three-month repeated oral dose toxicity study in juvenile dogs]. Hayashi, T; Karaki, K; Kato, I; Kimura, Y; Mizushima, Y; Moriyama, T; Nakano, M; Nishimura, K; Sawada, T; Yoneyama, S, 2001)	0.64
"Cefmatilen hydrochloride hydrate (S-1090) was administered daily by gavage to rats at doses of 100, 300 or 1000 mg potency/kg/day prior to and in the early stage of pregnancy to assess its adverse effects on parental reproductive ability and embryo-fetal development."	( [Reproductive and developmental toxicity studies of S-1090, cefmatilen hydrochloride hydrate (1)--A study on oral administration prior to and in the early stages of pregnancy in rats]. Hara, K; Hirashiba, M; Hishikawa, A; Ikeuchi, K; Kanamori, S; Kaneto, M; Kawai, M; Kishi, K; Muranaka, R; Muraoka, Y; Uchida, H; Yoshida, T, 2001)	2
" No adverse effects were observed in F2 offspring."	( [Reproductive and developmental toxicity studies of S-1090, cefmatilen hydrochloride hydrate (2)--A study on oral administration during the period of organogenesis in rats]. Hara, K; Hirashiba, M; Hishikawa, A; Ikeuchi, K; Kanamori, S; Kaneto, M; Kawai, M; Kishi, K; Muranaka, R; Uchida, H; Yoshida, T, 2001)	0.55
" No adverse effects were observed in F2 fetuses and offspring."	( [Reproductive and developmental toxicity studies of S-1090, cefmatilen hydrochloride hydrate (4)--A study on oral administration during the perinatal and lactation periods in rats]. Andou, M; Hara, K; Hirashiba, M; Hishikawa, A; Ikeuchi, K; Ito, M; Kanamori, S; Kaneto, M; Kawai, M; Kishi, K; Muranaka, R; Muraoka, Y; Uchida, H; Yoshida, T, 2001)	0.55

Dosage Studied

Excerpt	Relevance	Reference
" Diarrhea occurred on the dosing day and slightly soft feces lasted until 6 days after administration."	( [Toxicity study of cefmatilen hydrochloride hydrate (S-1090) (1)--Single oral and intravenous dose toxicity studies in rats]. Furukawa, H; Harihara, A; Kato, I; Kii, Y; Kitamura, T; Miyauchi, H; Muraoka, Y; Nishimura, K; Sato, K; Yabuuchi, K; Yahara, I, 2001)	0.64
" The changes observed in both studies were soft feces, abdominal distention, increased food and water consumption, decreases of urine volume and pH, and a decrease of blood neutrophils in almost all treated groups, reddish-brown feces (due to chelated products of S-1090 and its decomposition products with Fe3+ in the diet) in groups dosed at 300 mg potency/kg or more, and a lower mature granulocyte ratio in the bone marrow in groups dosed at 1000 mg potency/kg or more."	( [Toxicity study of cefmatilen hydrochloride hydrate (S-1090) (3)--One- and three-month repeated oral dose toxicity studies in rats]. Furukawa, H; Harihara, A; Hirata, M; Inoue, S; Kato, I; Kitamura, T; Moriyama, T; Muraoka, Y; Nishimura, K; Sato, K; Ueno, M; Yabuuchi, K, 2001)	0.64
" In the thyroids, an increased weight in some animals in the groups dosed at 100 mg potency/kg or more and an increased follicular colloid in the 400 mg potency/kg group were observed."	( [Toxicity study of cefmatilen hydrochloride hydrate (S-1090) (7)--Three-month repeated oral dose toxicity study in juvenile dogs]. Hayashi, T; Karaki, K; Kato, I; Kimura, Y; Mizushima, Y; Moriyama, T; Nakano, M; Nishimura, K; Sawada, T; Yoneyama, S, 2001)	0.64
" Loose and/or reddish brown feces were observed in both males and females of all the S-1090 dosing groups, and abdominal distention was also observed in males throughout the dosing period."	( [Reproductive and developmental toxicity studies of S-1090, cefmatilen hydrochloride hydrate (1)--A study on oral administration prior to and in the early stages of pregnancy in rats]. Hara, K; Hirashiba, M; Hishikawa, A; Ikeuchi, K; Kanamori, S; Kaneto, M; Kawai, M; Kishi, K; Muranaka, R; Muraoka, Y; Uchida, H; Yoshida, T, 2001)	0.55
" Loose or reddish-brown feces were observed in dams of all the S-1090 dosing groups."	( [Reproductive and developmental toxicity studies of S-1090, cefmatilen hydrochloride hydrate (2)--A study on oral administration during the period of organogenesis in rats]. Hara, K; Hirashiba, M; Hishikawa, A; Ikeuchi, K; Kanamori, S; Kaneto, M; Kawai, M; Kishi, K; Muranaka, R; Uchida, H; Yoshida, T, 2001)	0.55
" In dams, loose feces/reddish brown feces, increased cecum weight, decreased weights of the heart, spleen and submaxillary gland in all the S-1090 dosing groups and a decreased weight of the thymus in the 1000 mg potency/kg dosing group were observed."	( [Reproductive and developmental toxicity studies of S-1090, cefmatilen hydrochloride hydrate (4)--A study on oral administration during the perinatal and lactation periods in rats]. Andou, M; Hara, K; Hirashiba, M; Hishikawa, A; Ikeuchi, K; Ito, M; Kanamori, S; Kaneto, M; Kawai, M; Kishi, K; Muranaka, R; Muraoka, Y; Uchida, H; Yoshida, T, 2001)	0.55
"5% aqueous methylcellulose was administered by oral gavage up to 2000 mg/kg/day in single and double dosing groups."	( [Genotoxicity studies of cefmatilen hydrochloride hydrate (S-1090)]. Kondo, K; Miyajima, H; Miyake, Y; Nishimoto, Y; Shiratori, O; Takase, S, 2001)	0.61
" Vomiting, diarrhea or mucous feces occurred on the dosing day, and reddish-brown feces (due to chelated products of S-1090 and its decomposition products with Fe3+ in the diet) were also observed on the dosing and next day."	( [Toxicity study of cefmatilen hydrochloride hydrate (S-1090) (2)--Single oral dose toxicity study in dogs]. Furukawa, H; Harihara, A; Hirata, M; Inoue, S; Kato, I; Kimura, Y; Miyauchi, H; Nishimura, K; Sato, K; Ueno, M; Yabuuchi, K, 2001)	0.64
" Decreased intestinal flora were noted in all the groups treated with S-1090 or CFDN at the end of the dosing period."	( [Toxicity study of cefmatilen hydrochloride hydrate (S-1090) (5)--Six-month repeated oral dose toxicity study and supplement study in rats]. Chihaya, Y; Furukawa, H; Itoh, F; Kato, I; Mizushima, Y; Nishimura, Y; Ohno, K; Omori, M; Sameshima, H; Ueno, M; Yabuuchi, K; Yahara, I; Yoshida, I, 2001)	0.64

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	5 (25.00)	18.2507
2000's	15 (75.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.50 (24.57)
Research Supply Index	3.09 (2.92)
Research Growth Index	4.59 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.50)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	21 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
penicillin g Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.	2	1	penicillin allergen; penicillin	antibacterial drug; drug allergen; epitope
cephalothin Cephalothin: A cephalosporin antibiotic.. cefalotin : A semisynthetic, first-generation cephalosporin antibiotic with acetoxymethyl and (2-thienylacetyl)nitrilo moieties at positions 3 and 7, respectively, of the core structure. Administered parenterally during surgery and to treat a wide spectrum of blood infections.	2	1	azabicycloalkene; beta-lactam antibiotic allergen; carboxylic acid; cephalosporin; semisynthetic derivative; thiophenes	antibacterial drug; antimicrobial agent
cefmetazole Cefmetazole: A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.. cefmetazole : A second-generation cephalosporin antibiotic having N(1)-methyltetrazol-5-ylthiomethyl, {[(cyanomethyl)sulfanyl]acetyl}amino and methoxy side-groups at positions 3, 7beta and 7alpha respectively of the parent cephem bicyclic structure.	2	1	cephalosporin	antibacterial drug
cefotiam Cefotiam: One of the CEPHALOSPORINS that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.. cefotiam : A cephalosporin with ({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}sulfanyl)methyl and (2-amino-1,3-thiazol-4-yl)acetamido substituents at positions 3 and 7, respectively, of the cephem skeleton. A third generation beta-lactam cephalosporin antibiotic, it is active against a broad spectrum of both Gram positive and Gram negative bacteria.	2	1	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
cephalosporin c cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.	9.35	20	cephalosporin	fungal metabolite
cefdinir Cefdinir: A third-generation oral cephalosporin antibacterial agent that is used to treat bacterial infections of the respiratory tract and skin.. cefdinir : A cephalosporin compound having 7beta-2-(2-amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino- and 3-vinyl side groups.	2	1

Condition	Relationship Strength	Studies
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	3.71	10
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	2	1
Cystitis Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.	2	1
Glycosuria The appearance of an abnormally large amount of GLUCOSE in the urine, such as more than 500 mg/day in adults. It can be due to HYPERGLYCEMIA or genetic defects in renal reabsorption (RENAL GLYCOSURIA).	2	1
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	2	1
Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES.	2	1
Abnormalities, Drug-Induced Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.	2	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2	1
Allergy, Drug [description not available]	2	1
Drug Hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally.	2	1
Abnormalities, Autosome [description not available]	2	1
Bacterial Disease [description not available]	2.39	2
Infections, Respiratory [description not available]	1.98	1
Bacterial Infections Infections by bacteria, general or unspecified.	2.39	2
Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.	1.98	1
Urinary Tract Infections Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.	2.4	2
Bacteremia The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.	1.98	1
Female Genital Diseases [description not available]	1.99	1
Genital Diseases, Female Pathological processes involving the female reproductive tract (GENITALIA, FEMALE).	1.99	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2	1

chemdatabank.com